Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1150 mg double-blinded secukinumab
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
2150 mg open-label secukinumab
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
3300 mg double-blinded secukinumab
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
4SECUKINUMAB
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[8] 13, 37, 41, 46, 107, 160, 269, 271 💬
5Secukinumab (150 mg)
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
6Secukinumab (75 mg)
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
7Secukinumab (AIN457)
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 46 💬
8Secukinumab (AIN457) 150 mg s.c.
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
9Secukinumab 150 mg
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 41 💬
10Secukinumab 150 mg (2 injections per dose
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 269 💬
11Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
12Secukinumab 150 mg/1 ml Solution for injection
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[2] 37, 271 💬
13Secukinumab 150 mg/ml
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
14Secukinumab 150 milligram [Cosentyx]
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
15Secukinumab 150mg
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 37 💬
16Secukinumab 300 mg
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 41 💬
17Secukinumab 300 mg, s.c.
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 41 💬
18Secukinumab 300mg
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 37 💬
19Secukinumab 75 mg/0.5 ml Solution for injection
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 271 💬
20Secukinumab Injection
(D09967)		[1] Secukinumab[1] Secukinumab (D09967) 💬[1] IL17A 💬[6] Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬[1] 160 💬